tradingkey.logo
tradingkey.logo
Search

Vor Biopharma Inc

VOR
Add to Watchlist
21.150USD
-0.650-2.98%
Close 07-31 16:00ETQuotes delayed by 15 min
1.15BMarket Cap
LossP/E TTM

VOR Income Statement

You can find the annual or quarterly income statement of Vor Biopharma Inc here for insights into the performance and operational efficiency of Vor Biopharma Inc.
Quarterly
Quarterly+Annual
Quarterly
Annual
YOY
Hide blank rows
FY2026Q1
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021Q4
FY2021Q3
FY2021Q2
FY2021Q1
FY2020Q4
FY2020Q3
FY2020Q2
FY2020Q1
FY2019Q4
FY2019Q3
Operating expenses
5.61%35.16M
14.85%35.96M
-1.42%28.11M
844.67%274.28M
2.99%33.29M
11.33%31.31M
-19.26%28.51M
-9.76%29.04M
6.26%32.33M
13.75%28.12M
46.53%35.32M
47.64%32.17M
33.43%30.42M
35.07%24.73M
29.56%24.10M
18.56%21.79M
66.06%22.80M
16.87%18.31M
57.84%18.60M
128.61%18.38M
74.28%13.73M
298.75%15.66M
217.14%11.79M
--8.04M
--7.88M
--3.93M
--3.72M
R&D expenses
-34.10%17.59M
-24.29%19.19M
-35.18%14.14M
1098.27%261.50M
9.78%26.70M
21.30%25.35M
-20.97%21.82M
-8.68%21.82M
10.98%24.32M
22.48%20.90M
63.59%27.61M
55.85%23.90M
43.42%21.91M
34.42%17.06M
30.56%16.88M
18.22%15.33M
70.90%15.28M
12.03%12.69M
58.74%12.93M
117.07%12.97M
44.89%8.94M
282.25%11.33M
419.26%8.14M
--5.97M
--6.17M
--2.96M
--1.57M
Depreciation, depletion, and amortization
-96.61%28.00K
-99.12%23.00K
-99.78%2.00K
133.33%2.10M
-12.51%825.00K
188.89%2.60M
0.00%900.00K
0.00%900.00K
12.66%943.00K
42.41%900.00K
0.00%900.00K
56.52%900.00K
96.48%837.00K
58.00%632.00K
140.64%900.00K
43.75%575.00K
36.98%426.00K
65.29%400.00K
94.79%374.00K
280.95%400.00K
371.21%311.00K
490.24%242.00K
500.00%192.00K
--105.00K
--66.00K
--41.00K
--32.00K
Operating profit
-5.61%-35.16M
-14.85%-35.96M
1.42%-28.11M
-844.67%-274.28M
-2.99%-33.29M
-11.33%-31.31M
19.26%-28.51M
9.76%-29.04M
-6.26%-32.33M
-13.75%-28.12M
-46.53%-35.32M
-47.64%-32.17M
-33.43%-30.42M
-35.07%-24.73M
-29.56%-24.10M
-18.56%-21.79M
-66.06%-22.80M
-16.87%-18.31M
-57.84%-18.60M
-128.61%-18.38M
-74.28%-13.73M
-298.75%-15.66M
-217.14%-11.79M
---8.04M
---7.88M
---3.93M
---3.72M
Net non-operating interest income (expenses)
Non-operating interest income
388.82%3.94M
366.61%2.79M
81.45%1.73M
-55.10%537.00K
-47.11%805.00K
-67.85%599.00K
-55.13%954.00K
-45.51%1.20M
-23.48%1.52M
128.59%1.86M
579.23%2.13M
1550.38%2.19M
3057.14%1.99M
1409.26%815.00K
552.08%313.00K
1230.00%133.00K
800.00%63.00K
--54.00K
--48.00K
--10.00K
-75.86%7.00K
-100.00%0.00
-100.00%0.00
--0.00
--29.00K
--35.00K
--77.00K
Non-operating interest expense
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
--0.00
--0.00
----
----
--0.00
--0.00
Special income (expenses)
---188.36M
--1.76B
---790.46M
---1.30B
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
--0.00
--0.00
----
----
--0.00
--0.00
Other non-operating income (expenses)
----
--2.00K
--4.15M
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
Income before tax
-575.94%-219.59M
5709.72%1.72B
-2848.89%-812.68M
-5552.75%-1.57B
-5.46%-32.49M
-16.95%-30.71M
16.97%-27.56M
7.14%-27.84M
-8.34%-30.80M
-9.83%-26.26M
-39.52%-33.19M
-38.41%-29.98M
-25.05%-28.43M
-31.00%-23.91M
-28.21%-23.79M
-17.90%-21.66M
-65.69%-22.74M
-16.53%-18.25M
-57.44%-18.55M
-128.48%-18.37M
-74.84%-13.72M
-302.34%-15.66M
-223.85%-11.79M
---8.04M
---7.85M
---3.89M
---3.64M
Income after tax
-575.94%-219.59M
5709.72%1.72B
-2848.89%-812.68M
-5552.75%-1.57B
-5.46%-32.49M
-16.95%-30.71M
16.97%-27.56M
7.14%-27.84M
-8.34%-30.80M
-9.83%-26.26M
-39.52%-33.19M
-38.41%-29.98M
-25.05%-28.43M
-31.00%-23.91M
-28.21%-23.79M
-17.90%-21.66M
-65.69%-22.74M
-16.53%-18.25M
-57.44%-18.55M
-128.48%-18.37M
-74.84%-13.72M
-302.34%-15.66M
-223.85%-11.79M
---8.04M
---7.85M
---3.89M
---3.64M
Net income from continuous operations
-575.94%-219.59M
5709.72%1.72B
-2848.89%-812.68M
-5552.75%-1.57B
-5.46%-32.49M
-16.95%-30.71M
16.97%-27.56M
7.14%-27.84M
-8.34%-30.80M
-9.83%-26.26M
-39.52%-33.19M
-38.41%-29.98M
-25.05%-28.43M
-31.00%-23.91M
-28.21%-23.79M
-17.90%-21.66M
-65.69%-22.74M
-16.53%-18.25M
-57.44%-18.55M
-128.48%-18.37M
-74.84%-13.72M
-302.34%-15.66M
-223.85%-11.79M
---8.04M
---7.85M
---3.89M
---3.64M
Net income attributable to controlling interests
-575.94%-219.59M
5709.72%1.72B
-2848.89%-812.68M
-5552.75%-1.57B
-5.46%-32.49M
-16.95%-30.71M
16.97%-27.56M
7.14%-27.84M
-8.34%-30.80M
-9.83%-26.26M
-39.52%-33.19M
-38.41%-29.98M
-25.05%-28.43M
-31.00%-23.91M
-28.21%-23.79M
-17.90%-21.66M
-52.08%-22.74M
-2.35%-18.25M
-32.81%-18.55M
-106.52%-18.37M
-74.58%-14.95M
-305.39%-17.83M
-236.95%-13.97M
---8.89M
---8.56M
---4.40M
---4.15M
Net income attributable to common shareholders
-575.94%-219.59M
5709.72%1.72B
-2848.89%-812.68M
-5552.75%-1.57B
-5.46%-32.49M
-16.95%-30.71M
16.97%-27.56M
7.14%-27.84M
-8.34%-30.80M
-9.83%-26.26M
-39.52%-33.19M
-38.41%-29.98M
-25.05%-28.43M
-31.00%-23.91M
-28.21%-23.79M
-17.90%-21.66M
-52.08%-22.74M
-2.35%-18.25M
-32.81%-18.55M
-106.52%-18.37M
-74.58%-14.95M
-305.39%-17.83M
-236.95%-13.97M
---8.89M
---8.56M
---4.40M
---4.15M
Basic earnings per share
-1861.68%-5.11
19454.33%84.89
-30116.29%-121.63
-61539.21%-251.24
42.52%-0.26
-13.31%-0.44
18.01%-0.40
8.86%-0.41
-5.53%-0.45
26.41%-0.39
21.56%-0.49
22.70%-0.45
29.62%-0.43
-8.15%-0.53
-24.58%-0.63
-16.17%-0.58
-49.94%-0.61
2.79%-0.49
-28.18%-0.50
-99.58%-0.50
-69.24%-0.41
-305.38%-0.50
-236.95%-0.39
---0.25
---0.24
---0.12
---0.12
Diluted earnings per share
-1861.68%-5.11
19454.33%84.89
-30116.29%-121.63
-61539.21%-251.24
42.52%-0.26
-13.31%-0.44
18.01%-0.40
8.86%-0.41
-5.53%-0.45
26.41%-0.39
21.56%-0.49
22.70%-0.45
29.62%-0.43
-8.15%-0.53
-24.58%-0.63
-16.17%-0.58
-49.94%-0.61
2.79%-0.49
-28.18%-0.50
-99.58%-0.50
-69.24%-0.41
-305.38%-0.50
-236.95%-0.39
---0.25
---0.24
---0.12
---0.12
Dividend per share
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
Currency unit
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
Audit opinions
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----

FAQs

How do I read Vor Biopharma Inc's income statement on TradingKey?

Start with total revenue, then review cost of revenue, gross profit, operating expenses, operating profit, income before tax, net income, and EPS. Revenue shows the scale of the business, while margins and profit lines show whether that revenue is being converted into earnings efficiently.

What is the difference between quarterly and annual income statements?

A quarterly income statement shows performance for a three-month fiscal period, while an annual income statement summarizes the full fiscal year. Quarterly data is useful for tracking recent momentum and seasonality, while annual data is better for judging long-term growth, profitability, and business cycles.

What does YOY mean on the income statement page?

YOY means year over year. It compares a financial metric with the same period in the previous year, such as this quarter's revenue versus revenue in the same quarter last year. YOY comparison helps investors see growth trends while reducing the impact of normal seasonal changes.

Which income statement metrics matter most when analyzing VOR stock?

Important metrics include revenue growth, gross profit, gross margin, operating profit, operating margin, net income, EPS, R&D expenses, SG&A expenses, and tax expense. Investors usually look at these together to judge whether the company is growing, controlling costs, and improving profitability.

What was Vor Biopharma Inc's net income for the year?

Vor Biopharma Inc posted -695.98M in net income for fiscal year 2025.

How much net income did Vor Biopharma Inc post in the last quarter?

Vor Biopharma Inc reported -219.59M in net income for the latest quarter。

What was Vor Biopharma Inc's annual operating profit?

Vor Biopharma Inc's operating income was -341.94M for fiscal year 2025.

How is EPS related to the income statement?

EPS, or earnings per share, is based on net income divided by the number of shares outstanding. It helps investors understand how much profit the company generated for each share, but it should be reviewed alongside share count changes, margins, cash flow, and valuation metrics.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.